晚期胆道癌的化学免疫疗法:临床结果的元分析
Alireza Tojjari1, Sepideh Razi2, Osama M Younis3
1Department of Medicine, Division of Hematology & Oncology, University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA 15213, USA.
Biomedicines
|September 27, 2025
概括
化疗免疫疗法显著改善了晚期胆道癌 (BTCs) 的整体存活率 (OS) 和无进展存活率 (PFS),与单独的化疗相比. 这一发现支持化学免疫疗法作为BTC患者首选的一线治疗策略.
科学领域:
- 在瘤学瘤学.
- 胃肠病学 胃肠病学
- 免疫治疗是一种免疫疗法.
背景情况:
- 胆道癌 (BTC) 存在重大管理挑战,特别是在晚期,手术不是一种选择,化疗有效性有限的情况下.
- 免疫检查点抑制剂在BTC治疗中的作用仍然不确定,因为临床试验结果和终点不同.
研究的目的:
- 进行一项元分析,评估结合化疗与免疫治疗的疗效与晚期BTC单独化疗的疗效.
- 澄清化疗免疫治疗对BTC患者整体生存期 (OS) 和无进展生存期 (PFS) 的影响.
主要方法:
- 在PubMed,Embase,Web of Science和ClinicalTrials.gov上对RCT和前性比较研究 (2010-2024) 进行了系统的文献搜索.
- 固定效果的元分析被用来计算OS和PFS的聚合危险比率 (HRs),随机效应模型用于敏感性分析.
- 遵循了PRISMA 2020指南,并向OSF注册了审查.
主要成果:
- 两个RCT (n=1754) 表明,与单独化疗相比,化疗免疫疗法显著降低了20%的死亡风险 (OS HR=0.80) 和19%的疾病进展或死亡 (PFS HR=0.81).
- 敏感性分析证实了这些发现的稳定性和稳定性,没有发现显著的出版偏差.
- 另外两项研究的定性评估支持了定量发现.
结论:
- 化疗免疫疗法在高级BTC中比单独化疗提供了显著的生存益处 (改善OS和PFS).
- 这些发现支持将化疗免疫疗法作为高级BTC的标准一线治疗.
- 未来的研究应该专注于生物标志物识别以选择患者,并将化疗免疫疗法与向药物结合起来.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.9K
09:11Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
1.1K
相关概念视频
Tumor Immunotherapy
1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Cancer Survival Analysis
648
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
648
